Sanofi (SNW BE) stock market data APIs
€76.2024
0.73(1%)
as of March 18, 2026
Try our APIs with
free plan!
Sanofi Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for SNW.BE.
Prev. Close
76.2024
Open
76.9357
High
77.2448
Low
75.0267
52 wk Range
74.93-100.4904
Market Cap
108 619 M
EPS
1.79
Dividends (Yield)
0.0361
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Sanofi data using free add-ons & libraries
Get Sanofi Fundamental Data
Sanofi Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-24
- EPS/Forecast: 1.67
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sanofi News
New
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer
For Immediate Release Chicago, IL – March 3, 2026 – Today, Zacks Equity Research discusses Eli Lilly LLY, Johnson & Johnson JNJ, Sanofi SNY and Bayer BAYRY. Industry: Large-Cap Pharma Link: htt...
Is Sanofi (ENXTPA:SAN) Offering An Opportunity After A 19.5% One Year Share Price Fall
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. If you are wondering whether Sanofi shares offer good value...
Sanofi Says Acoziborole Winthrop for Sleeping Sickness Received Positive CHMP Opinion
Sanofi (SNY) said Friday the European Medicines Agency's Committee for Medicinal Products for Human PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscrip...
Alpha-1 Antitrypsin Deficiency Research Report 2025-2035: Market Enters Growth Phase as Established Augmentation Therapies Converge with Advancing Gene and RNA Pipelines
Company Logo Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic disorder caused by SERPINA1 gene mutations, leading to conditions like pulmonary emphysema and liver dysfunction. The AATD market ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
